8-K current report · filed Sep 17, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: September 17, 2026

Item 8.01Item 7.01AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Investor presentation for H.C. Wainwright’s 28th Annual Global Investor Conference on September 14, 2026.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation for H.C. Wainwright’s 28th Annual Global Investor Conference on September 14, 2026
  • Presentation targets institutional investors, analysts and other market participants
  • Exhibit 99.2 contains the substantive company update and may influence investor expectations

Item 8.01 · Other Events

  • NDA resubmitted to FDA for Anaphylm, a sublingual film for Type I allergic reactions including anaphylaxis
  • FDA resubmission reopens the regulatory review pathway for Aquestive’s lead product candidate
  • Anaphylm approval could expand treatment options beyond injectable epinephrine, subject to FDA review

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.